Nanoform, a pioneering nanoparticle medicine-enabling company, has announced a groundbreaking collaboration with AstraZeneca Plc. Under this partnership, Nanoform has granted AstraZeneca a global license to access STARMAP®, a digital AI version of the CESS® technology. STARMAP® facilitates in-silico experiments that aid in the selection of molecules for nanoforming. This strategic move will empower AstraZeneca to streamline its drug discovery processes, extending all the way to lifecycle management.
A transformative licensing agreement
The licensing agreement signifies a significant milestone in the partnership between Nanoform and AstraZeneca, building on years of early-stage collaboration. The successful completion of technology evaluation, including the implementation of STARMAP®, culminated in clinical candidate feasibility studies. Importantly, STARMAP® aligns seamlessly with AstraZeneca’s ambitious sustainability goals.
As part of the agreement, Nanoform will gain access to AstraZeneca’s compound libraries and vast datasets. This collaborative effort will allow Nanoform to conduct STARMAP® screening and propose innovative product development concepts and strategies in tandem with AstraZeneca.
Empowering drug discovery through STARMAP
STARMAP Online, created in response to the demand from Nanoform’s partners, offers a secure and efficient solution for conducting in-silico CESS® experiments. Key features include:
Security and safety: The interface adheres to ISO27001:2017 standards, ensuring the confidentiality of client submissions. Molecules can be screened without sharing their structures, and results are directly provided to clients.
Scalability and agility: STARMAP Online can handle thousands of molecules in a single submission, facilitating the selection of candidates from molecule libraries.
Novel insights: With a database housing 20,000 pre-analyzed, public-domain disclosed drugs and candidates, clients can request thematic evaluations and explore CESS® capabilities in various therapeutic areas, target classes, and disease areas.
Accelerating medicine development
“External collaboration is fundamental to advancing medicines into the hands of patients that need them. By combining Nanoform’s AI-based STARMAP approach and in-house nanotechnology expertise, we can help to accelerate AstraZeneca’s medicine development goals and support more patient- and planet-centric medicine development initiatives,” said Christian Jones, Chief Commercial Officer of Nanoform.
Nanoform is at the forefront of innovation in nanoparticle medicine, collaborating with pharmaceutical and biotech partners worldwide. The company’s platform technologies aim to provide new and improved medicines while reducing clinical attrition rates. Nanoform specializes in enhancing drug molecules’ performance through nanoforming technologies and formulation services, offering GMP manufacturing across the small to large molecule development spectrum. Nanoform’s shares are listed on the Premier-segment of Nasdaq First North Growth Market in Helsinki (ticker: NANOFH) and Stockholm (ticker: NANOFS).
This press release contains forward-looking statements, including Nanoform’s strategy, business plans, and focus. These statements are based on management’s current expectations and are subject to various risks and uncertainties. Nanoform cautions readers not to place undue reliance on forward-looking statements, as actual results may differ materially from those expressed or implied.